What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?

Clinical Endocrinology

Volumn 73, Issue 2, 2010, Pages 149-152

  Bartalena, Luigi ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AZATHIOPRINE; BOTULINUM TOXIN; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; OCTREOTIDE; PASIREOTIDE; PREDNISOLONE; PREDNISONE; RITUXIMAB; SOMATOSTATIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALGORITHM; ARTICLE; CLINICAL TRIAL; DECOMPRESSION SURGERY; DISEASE SEVERITY; DRUG MEGADOSE; ENDOCRINE OPHTHALMOPATHY; GRAVES DISEASE; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ALGORITHMS; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; INJECTIONS, INTRAVENOUS; METHYLPREDNISOLONE; PRACTICE GUIDELINES AS TOPIC; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 77954882866     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03783.x     Document Type: Article

References (28)

1. Bartalena, L. Tanda, M.L. (2009) Graves' ophthalmopathy. New England Journal of Medicine, 360, 994 1001.
2. Wiersinga, W.M. (2007) Combined thyroid-eye clinics. In:W.M. Wiersinga, G.J. Kahaly eds. Graves' Orbitopathy - A Multidisciplinary Approach. Karger
3. Perros, P., Baldeschi, L., Boboridis, K. et al. (2006) A questionnaire survey on the management of Graves' orbitopathy in Europe. European Journal of Endocrinology, 155, 207 211.
4. Perros, P., Crombie, A.L. Kendall-Taylor, P. (1995) Natural history of thyroid associated ophthalmopathy. Clinical Endocrinology, 42, 45 50.
5. Bartalena, L., Baldeschi, L., Dickinson, A. et al. (2008) Consensus statement of the European Group on Graves' orbitopathy (GO) on management of GO. European Journal of Endocrinology, 158, 273 285. (Pubitemid 351404990)
6. Bartalena, L. (2007) Prevention. In:W.M. Wiersinga, G.J. Kahaly eds. Graves' Orbitopathy - A Multidisciplinary Approach. Karger
7. Tallstedt, L., Lundell, G., Torring, O. et al. & the Thyroid Study Group (1992) Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. New England Journal of Medicine, 326, 1733 1738.
8. Bartalena, L., Marcocci, C., Bogazzi, F. et al. (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. New England Journal of Medicine, 338, 73 78. (Pubitemid 28042269)
9. Acharyia, S.H., Avenell, A., Philip, S. et al. (2008) Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clinical Endocrinology, 69, 943 950.
10. Traisk, F., Tallstedt, L., Abraham-Nordling, M. et al. & the Thyroid Study Group of TT 96 (2009) Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. Journal of Clinical Endocrinology & Metabolism, 94, 3700 3707.
11. Bartalena, L., Marcocci, C., Bogazzi, F. et al. (1989) Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism. New England Journal of Medicine, 321, 1349 1352. (Pubitemid 19284190)
12. Lai, A., Sassi, L., Compri, E. et al. (2010) Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. Journal of Clinical Endocrinology & Metabolism, January 10, 2010 [Epub ahead of print].
13. Terwee, C.B., Prummel, M.F., Gerding, M.N. et al. (2005) Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clinical Endocrinology, 62, 145 155.
14. Marcocci, C., Bartalena, L., Tanda, M.L. et al. (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. Journal of Clinical Endocrinology & Metabolism, 86, 3562 3567.
15. Kahaly, G.J., Pitz, S., Hommel, G. et al. (2005) Randomized, single-blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. Journal of Clinical Endocrinology & Metabolism, 90, 5234 5240.
16. Marinò, M., Morabito, E., Brunetto, M.R. et al. (2004) Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid, 14, 403 406.
17. Le Moli, R., Baldeschi, L., Saeed, P. et al. (2007) Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid, 17, 357 362.
18. Ohtsuka, K., Sato, A., Kawaguchi, S. et al. (2003) Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy. American Journal of Ophthalmology, 135, 285 290.
19. Dickinson, A.J., Vaidya, B., Miller, M. et al. (2004) Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. Journal of Clinical Endocrinology & Metabolism, 89, 5910 5915.
20. Wemeau, J.L., Caron, P., Beckers, A. et al. (2005) Octreotide (long-acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. Journal of Clinical Endocrinology & Metabolism, 90, 841 848.
21. Chang, T.-C. Liao, S.-L. (2006) Slow-release lanreotide in Graves' ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. Journal of Endocrinological Investigation, 29, 413 422.
22. Stan, M.N., Garrity, J.A., Bradley, E.A. et al. (2006) Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. Journal of Clinical Endocrinology & Metabolism, 91, 4817 4824.
23. Paridaens, D., van den Bosch, W.A., van der Loos, T.L. et al. (2005) The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye, 19, 1286 1289.
24. Prummel, M.F., Mourits, M.P., Berghout, L. et al. (1989) Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. New England Journal of Medicine, 321, 1353 1359.
25. Kahaly, G., Schrezenmeir, J., Krause, U. et al. (1986) Ciclosporin and prednisone vs. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. European Journal of Clinical Investigation, 16, 415 422.
26. El Fassi, D., Nielsen, C.H., Hasselbach, C.H. et al. (2006) Treatment-resistant severe, active Graves' ophthalmopathy successfully treated by B lymphocyte depletion. Thyroid, 16, 709 710.
27. Salvi, M., Vannucchi, G., Campi, I. et al. (2007) Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. European Journal of Endocrinology, 156, 33 40.
28. Chong, K.K., Khanna, D., Afifyan, N.F. et al. (2009) Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology, October 7, 2009. [Epub ahead of print].